

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10782968
Filing Date	2004-02-20
First Named Inventor	Williams
Art Unit	1643
Examiner Name	Harris Dent, Ph.D.
Attorney Docket Number	W1107/20009

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030166017	A1	2003-09-04	McCarthy	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10782968
Filing Date	2004-02-20
First Named Inventor	Williams
Art Unit	1643
Examiner Name	Harris
Attorney Docket Number	W1107/20009

1	Trzeciak MC et al., Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. Thromb. Res. 1985; 40:121-128.	<input type="checkbox"/>
2	Ffrench P et al., Comparative evaluation of plasma thrombospondin beta-thromboglobulin and platelet factor 4 in acute myocardial infarction. Thromb. Res. 1985; 39:619-624.	<input type="checkbox"/>
3	Dawes J et al., A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb. Res. 1983; 29: 569-581.	<input type="checkbox"/>
4	McCrohan MB et al., Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis. Thromb Haemost. 1987; 58:850-852	<input type="checkbox"/>
5	Huang S-W and Kao K-J, Plasma thrombospondin measurement in clinical practice. Internal Medicine for the Specialist. 1990. 11:52-70.	<input type="checkbox"/>
6	Tuszynski GP et al., Thrombospondin levels in patients with malignancy, Thromb Haemost 1992; 67:607-11.	<input type="checkbox"/>
7	Nathan FE et al., Plasma Thrombospondin levels in patients with gynecological malignancies. Cancer. 1994; 73:2853-8.	<input type="checkbox"/>
8	Yamashita Y et al., Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer. 1998; 82:632-8.	<input type="checkbox"/>
9	Topol EJ et al., "Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104:2641-2644.	<input type="checkbox"/>
10	Baenziger NL, et al., A thrombin-sensitive protein of human platelet membranes. Proc. Natl. Acad. Sci. USA. 1971;68:240-253 (Abstract only)	<input type="checkbox"/>
11	Gullu IH et al., Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer. 1998; 83:2043-45.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10782968
Filing Date	2004-02-20
First Named Inventor	Williams
Art Unit	1643
Examiner Name	Harris Dent, Ph.D.
Attorney Docket Number	W1107/20009

12	Asch AS, et al., Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Biophys Res Commun. 1992; 182:1208-1217.	<input type="checkbox"/>
13	Clezardin P, et al., Characterization of two murine monoclonal antibodies (P10, P12) directed against different determinants on human blood platelet thrombospondin. Eur J Biochem. 1986; 154:95-102. (Abstract only)	<input type="checkbox"/>
14	Albo D, et al., Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res. 2002; 108:51-60.	<input type="checkbox"/>
15	Wight TN, et al., Light microscopic immunolocalization of thrombospondin in human tissues. J Histochem Cytochem. 1985; 33:295-302. (Abstract only)	<input type="checkbox"/>
16	Serre CM, et al., Distribution of thrombospondin and integrin alpha V in DCIS, invasive ductal and lobular human breast carcinomas. Analysis by electron microscopy. Virchows Archiv. 1995; 427:365-372.	<input type="checkbox"/>
17	Matthias LJ, et al., Identification of monoclonal antibodies that recognize different disulfide bonded forms of thrombospondin 1. Biochim Biophys Acta. 1996; 1296: 138-144. (Abstract only)	<input type="checkbox"/>
18	Silverstein et al., Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest. 1985; 75:2065-73. (Abstract only)	<input type="checkbox"/>
19	Leung LL et al., Complex formation of platelet thrombospondin with histidine-rich glycoprotein. J Clin Invest. 1984; 73:5-12. (Abstract only)	<input type="checkbox"/>
20	Vastag B, Study concludes that moderate PSA levels are unrelated to prostate cancer outcomes. JAMA. 2002; 287:969-970.	<input type="checkbox"/>
21	Brostjan C et al., Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer. 2003; 98:2291-2301. (Abstract only)	<input type="checkbox"/>
22	Qian X et al., Expression of Thrombospondin-1 in Human Pancreatic Adenocarcinomas: role in matrix metalloproteinase-9 production. Pathology Oncology Res. 2001; 7:251-259.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10782968
Filing Date	2004-02-20
First Named Inventor	Williams
Art Unit	1643
Examiner Name	Harris
Attorney Docket Number	W1107/20009

23	Gladson CL. The role of TSP-1 and 2 in the biology of astrocytomas. NIH grant. 2002, Number 5R01CA097110-02. (Abstract Only)	<input type="checkbox"/>
24	Tuszynski, GP. Angiocidin, A new angiogenesis inhibitor. NIH grant. 2001. Number 7R01CA088931-02. (Abstract only)	<input type="checkbox"/>
25	Tuszynski, GP. Antimetastatic effect of Thrombospondin derived from peptides. NIH grant. 2001. Number 1R41CA081822-01A2. (Abstract only)	<input type="checkbox"/>
26	Huang SW and Kao KJ, Use of thrombospondin level to predict the clinical course of atopic dermatitis associated with food hypersensitivity or skin infection. J Dermatol Sci. 1996; 11:59-63. (Abstract only)	<input type="checkbox"/>
27	Figure 1: Structural and functional domains of thrombospondin-1. 2002. http://research.bidmc.harvard.edu/Pathology/images/tspl.jpg ,	<input type="checkbox"/>
28	Huang S-W et al., Plasma Thrombospondin levels in sheep with allergic asthma. Chest. 1996; 109: 1614-1617.	<input type="checkbox"/>
29	Aiken ML, Isolation and characterization bovine platelet thrombospondin (protein). Dissertation. Wayne State University. 1984. (Abstract only)	<input type="checkbox"/>
30	Rice AJ, et al., Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma of the breast. J Clin Pathol. 2002; 55:921-925. (Abstract only)	<input type="checkbox"/>
31	Goddard JC, et al., Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. Eur Urol. 2002; 42:464-468. (Abstract only)	<input type="checkbox"/>
32	Mascaux C, et al., Expression of thrombospondin in non-small cell lung cancer. Anticancer Res. 2002; 22:1273-1277. (Abstract only)	<input type="checkbox"/>
33	Qin LX, et al., The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 2002; 8:385-392. (Abstract only)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10782968
Filing Date	2004-02-20
First Named Inventor	Williams
Art Unit	1643
Examiner Name	Harris
Attorney Docket Number	W1107/20009

34	Wakiyama T, et al., The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol Histopathol. 2001; 16:345-351. (Abstract only)	<input type="checkbox"/>
35	Kuroi K, et al., Circulating angiogenesis regulators in cancer patients. Int J Biomarkers. 2001; 16: 5-26. (Abstract only)	<input type="checkbox"/>
36	Kasper HU, et al., Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch. 2001;438:116-120. (Abstract only)	<input type="checkbox"/>
37	Tuszynski GP, et al., The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays. 1996; 18: 71-76. (Abstract only)	<input type="checkbox"/>
38	Wang TN, et al., The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen. Am J surg. 1995; 170:502-505. (Abstract only)	<input type="checkbox"/>
39	Clezardin P, et al., Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res. 1993; 53: 1421-1430. (Abstract only)	<input type="checkbox"/>
40	Frieda S, et al., Recombinant GST/CD36 fusion proteins define a thrombospondin binding domain. Evidence for a single calcium-dependent binding site on CD 36. J Biol Chem. 1995; 270:2981-2986. (Abstract only)	<input type="checkbox"/>
41	Arnoletti JP et al., Computer-assisted analysis of tumor sections for a new thrombospondin receptor. Am J Surg. 1994; 168:433-436. (Abstract only)	<input type="checkbox"/>
42	Begany A, et al., Expression of thrombospondin-1 (TSP1) and its receptor (CD36) in healthy and diseased human skin. Acta Derm Venereol. 1994; 74: 269-272. (Abstract only)	<input type="checkbox"/>
43	Tuszynski GP and Nicosia, RF, Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest. 1994; 70:228-233. (Abstract only)	<input type="checkbox"/>
44	Walz DA, et al., Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer Metastasis Rev. 1992; 11: 313-324. (Abstract only)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10782968
Filing Date	2004-02-20
First Named Inventor	Williams
Art Unit	1643
Examiner Name	Harris
Attorney Docket Number	W1107/20009

45	Wong SY, et al., Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am J Pathol. 1992; 142: 1473-1482. (Abstract only)	<input type="checkbox"/>
46	Adams JC et al., The thrombospondin gene family, Springer Verlag New York. 1995; page 107.	<input type="checkbox"/>
47	Wang-Rodriguez J et al., Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 2003; 5:R136-143.	<input type="checkbox"/>
48	Zhang J et al. Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. 2003. Virchows Archiv. 442: 563-568. (Abstract only)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Alana Harris Dent, Ph.D./	Date Considered	12 June 2011
--------------------	----------------------------	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.